Article thumbnail

Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum

By Astrid E. Greijer, Pien M. Delis-van Diemen, Remond J. A. Fijneman, Rachel H. Giles, Emile E. Voest, Victor W. M. van Hinsbergh and Gerrit A. Meijer

Abstract

Expression of the transcription factor hypoxia-inducible factor 1 (HIF-1), which plays a key role in cellular adaptation to hypoxia, was investigated in normal colorectal mucosa (ten), adenomas (61), and carcinomas (23). Tissue samples were analyzed for HIF-1α, its upstream regulators, von Hippel–Lindau factor, AKT, and mammalian target of rapamycin (mTOR) and its downstream targets glucose transporter 1 (GLUT1), carbonic anhydrase IX, stromal-cell-derived factor 1 (SDF-1) by immunohistochemistry. In normal colorectal mucosa, HIF-1α was observed in almost all nuclei of surface epithelial cells, probably secondary to a gradient of oxygenation, as indicated by pimonidazole staining. The same staining pattern was present in 87% of adenomas. In carcinomas, HIF-1α was present predominantly around areas of necrosis (78%). Active AKT and mTOR, were present in all adenomas, carcinomas, and in normal colorectal mucosa. GLUT1 and SDF-1 were present in the normal surface epithelium of all adenoma cases, whereas in the carcinoma GLUT1 was located around necrotic regions and SDF-1 was present in all epithelial cells. In conclusion, HIF-1α appears to be physiologically expressed in the upper part of the colorectal mucosa. The present observations support that upregulation of HIF-1α and its downstream targets GLUT1 and SDF-1 in colorectal adenomas and carcinomas may be due to hypoxia, in close interaction with an active phosphatidylinositol 3-kinases–AKT–mTOR pathway

Topics: Original Article
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2329727
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2002). AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis.
  2. (2005). Akt-regulated pathways in prostate cancer.
  3. (2001). Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer.
  4. (2005). Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
  5. (2003). Colonic polyposis caused by mTOR-mediated chromosomal instability
  6. (2005). CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity.
  7. (2002). CXCR4/CXCL12 expression and signalling in kidney cancer.
  8. (2004). Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.
  9. (2003). Expression of hypoxia-inducible factor1alpha is associated with tumor vascularization in human colorectal carcinoma.
  10. (2003). Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia- responsive enhancer.
  11. (2003). GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.
  12. (2001). Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (hif-1alpha) synthesis: novel mechanism for hif-1-mediated vascular endothelial growth factor expression.
  13. (2001). HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
  14. (2006). Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers.
  15. (2000). Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
  16. (1998). Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation.
  17. (2006). Interplay between VHL/ HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis.
  18. (2001). Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
  19. (2003). Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
  20. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
  21. (2004). Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells.
  22. (2004). Mutation of the von Hippel–Lindau (VHL) gene in human Virchows Arch
  23. (1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.
  24. (2002). Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma.
  25. (2002). Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
  26. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.
  27. (2004). Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase2 expression.
  28. (2001). Regulation of translation initiation by FRAP/mTOR.
  29. (2006). Shvarts A
  30. (2005). Stromal cell-derived factor-1 alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel–Lindau loss-offunction induces expression of a ligand and its receptor.
  31. (2007). Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas.
  32. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/ CXCL12 secretion.
  33. (2003). Targeting HIF-1 for cancer therapy.
  34. (2001). Targeting of HIFalpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
  35. (1999). The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis.
  36. (2005). Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.
  37. (2001). Transcriptional response to hypoxia in human tumors.
  38. (2005). Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1).
  39. (2006). VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells.
  40. (1996). von Hippel–Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Hum Pathol 27:152–156 544 Virchows Arch